Vicore Pharma - Interim report April-June 2023 : vimarsana.c

Vicore Pharma - Interim report April-June 2023 Stockholm, August 24, 2023 - Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the second quarter 2023.Important ev...

Related Keywords

Stockholm , Sweden , Swedish , Michael Buschle , Vicore Pharma , Carl Johan Dalsgaard , Ahmed Mousa , Hans Jeppsson , Pieris Pharmaceuticals , Vicore Pharma Holding , Vicore Pharma Us Inc , Pharma Holding , Chief Business Officer , Johan Dalsgaard , Securities Markets , Nasdaq Stockholm ,